Literature DB >> 1626052

Linear-quadratic analysis of radiosensitization by halogenated pyrimidines. I. Radiosensitization of human colon cancer cells by iododeoxyuridine.

E M Miller1, J F Fowler, T J Kinsella.   

Abstract

Radiosensitization by iododeoxyuridine (IdU) is a method of enhancing cell killing in the radiotherapy of human cancers, especially for tumors that proliferate faster than the surrounding normal tissues, such as might appear in brain or liver. We have investigated in vitro the relationship between the amount of thymidine replacement by IdU and the resulting radiosensitization in two human colon cancer cell lines, HCT 116 and HT 29, with differing inherent sensitivities to X rays. The results show that an increase in the initial slope of the cell survival curve was the predominant mode of radiosensitization. In this situation, the emphasis on changes in the initial slope suggest the use of a survival curve model that contains the initial slope as a defined variable, which the traditional single-hit, multitarget model does not. We present our analyses mainly in terms of alpha (initial slope) and changes in surviving fraction at 2 Gy and also as a modified form of sensitizer enhancement ratio that describes the dose-modifying factor of IdU at a single radiation dose of 2 Gy (SER 2 Gy). Iododeoxyuridine is an effective radiosensitizer in both cell lines, but IdU appears especially effective in increasing the initial slope of the more radioresistant line, the HT 29 cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1626052

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  6 in total

1.  Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI.

Authors:  S W Young; F Qing; A Harriman; J L Sessler; W C Dow; T D Mody; G W Hemmi; Y Hao; R A Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

2.  The limiting radiosensitisation of tumours by S-phase sensitisers.

Authors:  J F Fowler; T J Kinsella
Journal:  Br J Cancer Suppl       Date:  1996-07

3.  Phase I and Pharmacology Study of Ropidoxuridine (IPdR) as Prodrug for Iododeoxyuridine-Mediated Tumor Radiosensitization in Advanced GI Cancer Undergoing Radiation.

Authors:  Timothy Kinsella; Howard Safran; Susan Wiersma; Thomas DiPetrillo; Andrew Schumacher; Kayla Rosati; John Vatkevich; Lawrence W Anderson; Kimberly D Hill; Charles Kunos; Jerry M Collins
Journal:  Clin Cancer Res       Date:  2019-07-23       Impact factor: 12.531

4.  Incorporation of iododeoxyuridine in multicellular glioma spheroids: implications for DNA-targeted radiotherapy using Auger electron emitters.

Authors:  A Neshasteh-Riz; W J Angerson; J R Reeves; G Smith; R Rampling; R J Mairs
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Enhancement of IUdR Radiosensitization by Low-Energy Photons Results from Increased and Persistent DNA Damage.

Authors:  Emilie Bayart; Frédéric Pouzoulet; Lucie Calmels; Jonathan Dadoun; Fabien Allot; Johann Plagnard; Jean-Luc Ravanat; André Bridier; Marc Denozière; Jean Bourhis; Eric Deutsch
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

6.  Targeted radiosensitisation by pegylated liposome-encapsulated 3', 5'-O-dipalmitoyl 5-iodo-2'-deoxyuridine in a head and neck cancer xenograft model.

Authors:  K J Harrington; K N Syrigos; P S Uster; A Zetter; C R Lewanski; W J Gullick; R G Vile; J S W Stewart
Journal:  Br J Cancer       Date:  2004-07-19       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.